{"id":45328,"date":"2026-01-19T07:02:00","date_gmt":"2026-01-19T00:02:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=45328"},"modified":"2026-01-19T07:02:00","modified_gmt":"2026-01-19T00:02:00","slug":"harbour-biomed-acquires-common-stock-in-spruce-biosciences-deepening-strategic-collaboration","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=45328","title":{"rendered":"Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span>, ROTTERDAM, Netherlands<\/span> and SHANGHAI<\/span>, Jan. 19, 2026<\/span><\/span> \/PRNewswire\/ — Harbour\u00a0BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery\u00a0and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in\u00a0Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1]<\/sup>.<\/p>\n

\n<\/div>\n

The warrant was originally issued to Harbour BioMed’s subsidiary\u00a0and other minority shareholders\u00a0of HBM Alpha Therapeutics (“HBMAT”), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration aims to advance the development of SPR202 (formerly known as HBM9013 by Harbour BioMed), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders, including congenital adrenal hyperplasia.<\/p>\n

Dr. Jingsong Wang<\/span>, Founder, Chairman, and CEO of Harbour BioMed, stated: “This warrant exercise marks a significant milestone in our relationship with Spruce Biosciences. It moves us beyond a traditional licensor-licensee relationship to a truly aligned strategic partnership, reinforcing our shared commitment to accelerating the development of transformative therapies for patients worldwide.”<\/p>\n

\n\n\n\n
\n

[1]<\/sup>\u00a0Calculated based on the total outstanding shares and fully diluted shares of Spruce as of September 30, 2025.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

About Harbour BioMed<\/b><\/p>\n

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery\u00a0and development\u00a0of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.<\/p>\n

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice\u00ae<\/sup>,\u00a0generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE\u00ae<\/sup>) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM<\/sup>) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice\u00ae<\/sup>, HBICE\u00ae<\/sup>, and HBICATM<\/sup>\u00a0with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit\u00a0www.harbourbiomed.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CAMBRIDGE, Mass.<\/span>, ROTTERDAM, Netherlands<\/span> and SHANGHAI<\/span>, Jan. 19, 2026<\/span><\/span> \/PRNewswire\/ — Harbour\u00a0BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery\u00a0and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in\u00a0Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1]<\/sup>.<\/p>\n

\n<\/div>\n

The warrant was originally issued to Harbour BioMed’s subsidiary\u00a0and other minority shareholders\u00a0of HBM Alpha Therapeutics (“HBMAT”), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration aims to advance the development of SPR202 (formerly known as HBM9013 by Harbour BioMed), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders, including congenital adrenal hyperplasia.<\/p>\n

Dr. Jingsong Wang<\/span>, Founder, Chairman, and CEO of Harbour BioMed, stated: “This warrant exercise marks a significant milestone in our relationship with Spruce Biosciences. It moves us beyond a traditional licensor-licensee relationship to a truly aligned strategic partnership, reinforcing our shared commitment to accelerating the development of transformative therapies for patients worldwide.”<\/p>\n

\n\n\n\n
\n

[1]<\/sup>\u00a0Calculated based on the total outstanding shares and fully diluted shares of Spruce as of September 30, 2025.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

About Harbour BioMed<\/b><\/p>\n

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery\u00a0and development\u00a0of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.<\/p>\n

Harbour BioMed’s proprietary antibody technology platform, Harbour Mice\u00ae<\/sup>,\u00a0generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE\u00ae<\/sup>) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM<\/sup>) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice\u00ae<\/sup>, HBICE\u00ae<\/sup>, and HBICATM<\/sup>\u00a0with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit\u00a0www.harbourbiomed.com<\/a>.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-45328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/45328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45328"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/45328\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}